Literature DB >> 110152

Intraocular penetration of trifluridine.

D Pavan-Langston, D J Nelson.   

Abstract

We studied intraocular penetration of topically applied trifluridine in five patients with herpetic keratitis undergoing penetrating keratoplasty. We compared the concentration of trifluridine and its metabolite 5-carboxy 2'-deoxyuridine in the aqueous humor to those of normal control patients undergoing routine cataract extraction without preoperative antiviral therapy. Significant concentrations of intact trifluridine were achieved in the acqueous humor after topical application of 1% trifluridine ophthalmic drops. The metabolite, 5-carboxy 2'-deoxyuridine, was not found in the aqueous humor. Unlike idoxuridine and vidarabine, it is possible to achieve therapeutic levels of trifluridine at intraocular sites that would be advantageous in the treatment of deep herpetic disease involving the stroma and iris.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 110152     DOI: 10.1016/0002-9394(79)90360-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Herpes simplex virus ocular infections: current concepts of acute, latent and reactivated disease.

Authors:  D Pavan-Langston
Journal:  Trans Am Ophthalmol Soc       Date:  1990

Review 2.  Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

3.  Herpetic iridocyclitis.

Authors:  K R Wilhelmus; M G Falcon; B R Jones
Journal:  Int Ophthalmol       Date:  1982-02       Impact factor: 2.031

4.  Acute Herpetic Keratitis: What is the Role for Ganciclovir Ophthalmic Gel?

Authors:  Afsun Sahin; Pedram Hamrah
Journal:  Ophthalmol Eye Dis       Date:  2012-04-19

Review 5.  Adoption of Innovation in Herpes Simplex Virus Keratitis.

Authors:  James Chodosh; Lawson Ung
Journal:  Cornea       Date:  2020-11       Impact factor: 3.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.